A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more DMARDs

Trial Profile

A double-blind, randomized, placebo controlled, dose escalation, multi-center phase I/II trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with active rheumatoid arthritis who have previously failed one or more DMARDs

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2013

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Nov 2013 The extension study has been discontinued as the sponsor is no longer developing IV ofatumumab for rheumatoid arthritis, according to the Clinicaltrials.gov record.
    • 05 Nov 2013 The extension study has been discontinued as the sponsor is no longer developing IV ofatumumab for rheumatoid arthritis, according to the Clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top